Ivermectin, a controversially-discussed drug in the context of the COVID-19 pandemic, was found in a 2020 study from Peru to significantly reduce COVID-related deaths. With the backing of a peer-reviewed publication, this assertion is more potent than ever.
Dr. Pierre Kory, an early advocate for Ivermectin in the treatment of COVID-19, highlighted this particular study. At the time, it was merely a preprint - meaning it hadn’t undergone the rigorous peer-review process that acts as a hallmark for credible scientific research. Yet, the data was compelling enough for Dr. Kory and his associates at the FLCCC to champion widespread Ivermectin distribution.
Detractors pointed out the lack of peer review, dismissing the study and likening Ivermectin's use for COVID-19 to “taking horse medicine.” Fast forward two years, and this once-dismissed preprint has been rigorously examined and accepted by a renowned scientific journal.

Breaking Down the Study
The study delved into the effectiveness of Ivermectin in reducing excess COVID-19-related deaths across Peru’s 25 states in 2020. It was observed that different regions implemented varying degrees of Ivermectin distribution. While some states went all out and distributed maximum doses, others adopted a moderate approach, and a few limited its distribution.

Ivermectin is vindicated — but it’s also too little too late.
Dr. McCullough has reported that about 97% of Americans have already developed natural immunity to COVID-19, which offers strong and robust protection. And after mass COVID vaccination has nearly come to a complete halt, the FDA has now finally admitted that doctors can freely prescribe ivermectin for COVID. The timing, by no stretch, is suspicious.
Want to see more content like this? Subscribe to Vigilant News below to receive updates on the latest and most newsworthy stories.
